Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment - PubMed (original) (raw)

. 2016 Dec;56(12):2948-2952.

doi: 10.1111/trf.13860. Epub 2016 Nov 2.

Affiliations

Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment

Shawn D Keil et al. Transfusion. 2016 Dec.

Abstract

Background: Middle East respiratory syndrome coronavirus (MERS-CoV) has been identified as a potential threat to the safety of blood products. The Mirasol Pathogen Reduction Technology System uses riboflavin and ultraviolet (UV) light to render blood-borne pathogens noninfectious while maintaining blood product quality. Here, we report on the efficacy of riboflavin and UV light against MERS-CoV when tested in human plasma.

Study design and methods: MERS-CoV (EMC strain) was used to inoculate plasma units that then underwent treatment with riboflavin and UV light. The infectious titers of MERS-CoV in the samples before and after treatment were determined by plaque assay on Vero cells. The treatments were initially performed in triplicate using pooled plasma (n = 3) and then repeated using individual plasma units (n = 6).

Results: In both studies, riboflavin and UV light reduced the infectious titer of MERS-CoV below the limit of detection. The mean log reductions in the viral titers were ≥4.07 and ≥4.42 for the pooled and individual donor plasma, respectively.

Conclusion: Riboflavin and UV light effectively reduced the titer of MERS-CoV in human plasma products to below the limit of detection, suggesting that the treatment process may reduce the risk of transfusion transmission of MERS-CoV.

© 2016 AABB.

PubMed Disclaimer

Conflict of interest statement

SD and SM are employees of Terumo BCT, the manufacturer of the technology described in this article. RB has no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Stramer SL. Current perspectives in transfusion‐transmitted infectious diseases: emerging and re‐emerging infections. ISBT Sci Ser 2014;9:30–6. - PMC - PubMed
    1. Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med 2015;13:210. - PMC - PubMed
    1. Kingdom of Saudi Arabia, Ministry of Health . MERS‐CoV Statistics. [cited 2015 Sep 27] Available from: http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx.
    1. World Health Organization. Middle East respiratory syndrome coronavirus (MERS‐CoV) ; MERS‐CoV in Republic of Korea at a glance. World Health Organization. [cited 2015 Sep 28] Available from: http://www.wpro.who.int/outbreaks_emergencies/wpro_coronavirus/en/.
    1. Rha B, Rudd J, Feikin D, et al. Centers for Disease Control and Prevention. Update on the epidemiology of Middle East respiratory syndrome coronavirus (MERS‐CoV) infection, and guidance for the public, clinicians, and public health authorities—January 2015. MMWR Morb Mortal Wkly Rep 2015;64:61–2. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources